Cargando…
Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
BACKGROUND: Based on theoretical and preclinical results, terbium-161 may be a valid alternative to lutetium-177 and yttrium-90 in radionuclide therapies. The large low-energy electron emission from terbium-161 is a favorable feature in the treatment of disseminated disease, but its impact on the ra...
Autores principales: | Hemmingsson, Jens, Svensson, Johanna, van der Meulen, Nicholas P., Müller, Cristina, Bernhardt, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509518/ https://www.ncbi.nlm.nih.gov/pubmed/36153386 http://dx.doi.org/10.1186/s40658-022-00495-7 |
Ejemplares similares
-
(68)Gallium- and (90)Yttrium-/(177)Lutetium: “theranostic twins” for diagnosis and treatment of NETs
por: Werner, Rudolf A., et al.
Publicado: (2014) -
Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms
por: Saracyn, Marek, et al.
Publicado: (2022) -
Dosimetric Analysis of the Short-Ranged Particle Emitter (161)Tb for Radionuclide Therapy of Metastatic Prostate Cancer
por: Bernhardt, Peter, et al.
Publicado: (2021) -
Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study
por: Bober, Barbara, et al.
Publicado: (2022) -
Terbium-161 for PSMA-targeted radionuclide therapy of
prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)